SOPHiA GENETICS Reports Second Quarter 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Morgan Stanley Downgrades Sophia Genetics SA (SOPH) to Equalweight, 'Macro Weighs On Qtr/Guide'
August 7, 2024 11:31 AM EDTMorgan Stanley analyst Tejas Savant downgraded Sophia Genetics SA (NASDAQ: SOPH) from Overweight to Equalweight with a price target of $5.00 (from $10.00).
The analyst comments "2Q miss on macro-related biopharma/EMEA headwinds; though leading indicators remain positive, guidance cut reflects achievable 2H ramp despite... More
SOPHiA GENETICS SA (SOPH) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY24 Revenue Guidance
August 6, 2024 6:51 AM EDTSOPHiA GENETICS SA (NASDAQ: SOPH) reported Q2 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $16 million versus the consensus estimate of $17.4 million.
GUIDANCE:
SOPHiA GENETICS SA sees FY2024 revenue of $65-67 million, versus the... More
